# Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome

> **NCT02343133** · PHASE2 · COMPLETED · sponsor: **Neumedicines Inc.** · enrollment: 200 (actual)

## Conditions studied

- Hematopoietic Syndrome Due to Acute Radiation Syndrome

## Interventions

- **BIOLOGICAL:** HemaMax
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02343133
- **Lead sponsor:** Neumedicines Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2018-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02343133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02343133, "Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02343133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*